RxDoctor Payments Data

Nicholas de Maria, MD

Internal Medicine · Sicklerville, NJNPI 1942255286

Payments from drug & device makers

$12,061in general payments, 2019–2025

Across 924 payments — averaging $13.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$775
  • Lilly USA, LLC$733
  • Boehringer Ingelheim$665
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$12,057100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,061 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$163,865
Medicare patients
389
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$161,382
EliquisApixaban129$154,289
JardianceEmpagliflozin69$109,647
JanuviaSitagliptin Phosphate70$88,807
MyrbetriqMirabegron64$51,458
MounjaroTirzepatide18$40,214
TradjentaLinagliptin29$39,447
KerendiaFinerenone23$37,850
TrulicityDulaglutide17$32,986
XareltoRivaroxaban25$30,298
FarxigaDapagliflozin Propanediol24$29,179
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog31$23,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$16,800
Breo ElliptaFluticasone/Vilanterol22$13,729
Dexlansoprazole DrDexlansoprazole15$9,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,181$161,38286 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$665$156,909113 claims
PfizerEliquis$775$154,289129 claims
MerckJanuvia$486$88,80770 claims
Lilly USA, LLCMounjaro, Trulicity$733$73,20035 claims
Astellas Pharma US IncMyrbetriq$16$51,45864 claims
BayerKerendia$657$37,85023 claims
GSKTrelegy Ellipta, Breo Ellipta$658$30,52944 claims
Johnson & JohnsonXarelto$461$30,29825 claims
AstraZenecaFarxiga$1,159$29,17924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Sicklerville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →